


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (original) A method for reducing inflammation in a subject, the method comprising administering an anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of Compound I



or a pharmaceutically acceptable salt thereof to the subject in need of such treatment.

Claim 2. (original) The method of claim 1 wherein the pharmaceutically acceptable salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I is an acid addition salt.

Claim 3. (original) The method of claim 1 wherein the pharmaceutically acceptable salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula I is a monomethanesulfonate salt.

Claim 4. (previously presented) The method of claim 1 wherein the inflammation involves monocytes.

Claim 5. (previously presented) The method of claim 4 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes.

Claim 6. (original) The method of claim 4 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.

Claim 7. (original) The method of claim 1 wherein the inflammation is chronic.

Claim 8. (original) The method of claim 1 wherein the inflammation is acute.

Claim 9. (original) The method of claim 1 wherein the subject is a mammal.

Claim 10. (original) The method of claim 9 wherein the subject is a human subject.

Claim 11. (previously presented) The method of claim 1 wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.

Claim 12. (original) The method of claim 11 wherein the anti-inflammatory effective amount is in the range from 50 mg to 600 mg.

Claims 13-27 (canceled)

Claim 28. (previously presented) The method of claim 2 wherein the inflammation involves monocytes.

Claim 29. (previously presented) The method of claim 28 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes.

Claim 30. (previously presented) The method of claim 28 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.

Claim 31. (previously presented) The method of claim 3, wherein the inflammation involves monocytes.

Claim 32. (previously presented) The method of claim 31 wherein the inflammation involves macrophage colony stimulating factor (M-CSF)-stimulated monocytes.

Claim 33. (previously presented) The method of claim 31 wherein the inflammation is involved in conditions selected from the group consisting of autoimmune diseases, arthritis, and lung injuries.

Claim 34. (previously presented) The method of claim 2 wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.

Claim 35. (previously presented) The method of claim 3 wherein the anti-inflammatory effective amount of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or pharmaceutically acceptable salt thereof is in the range from 10 mg to 1000 mg.